TABLE 2

¹⁸F-FDG SUV, ¹⁸F-FES SUV, and ¹⁸F-FDG/FES SUV Ratio of Primary Tumor According to Various Clinical Factors

		¹⁸F-FDG SUV		¹⁸F-FES SUV		¹⁸F-FDG/FES SUV ratio
Variable	Patients (n)	Mean ± SE	P	Mean ± SE	P	Mean ± SE	P
Age (y)
<50	15	9.21 ± 1.06	0.447	4.82 ± 0.55	0.272	2.59 ± 0.54	0.895
≥50	52	8.76 ± 0.80		4.05 ± 0.28		3.11 ± 0.27
FIGO stage
I–II	54	8.02 ± 0.66	0.030^*	4.54 ± 0.25	0.015^*	2.23 ± 0.27	<0.001^*
III–IV	13	12.42 ± 1.73		2.92 ± 0.63		6.27 ± 1.32
Histology
Endometrioid G1 and G2	49	8.81 ± 0.80	0.658	4.81 ± 0.26	<0.001^*	2.20 ± 0.30	0.002^*
G3 and others	18	9.02 ± 1.13		2.63 ± 0.40		5.32 ± 1.05
Myometrial invasion
<1/2	47	7.94 ± 0.77	0.023^*	4.47 ± 0.29	0.166	2.55 ± 0.46	0.010^*
≥1/2	20	11.00 ± 1.17		3.66 ± 0.46		4.03 ± 0.65
Tumor size
<2 cm	24	5.50 ± 0.91	<0.001^*	4.70 ± 0.38	0.133	1.26 ± 0.19	<0.001^*
≥2 cm	43	10.67 ± 0.76		3.96 ± 0.32		3.93 ± 0.52
LVSI
Absent	41	7.91 ± 0.73	0.116	4.90 ± 0.27	<0.001^*	1.88 ± 0.25	<0.001^*
Present	26	10.40 ± 1.23		3.15 ± 0.40		4.81 ± 0.80
Lymph node metastasis
Absent	60	8.33 ± 0.64	0.041^*	4.52 ± 0.25	0.001^*	2.52 ± 0.35	<0.001^*
Present	7	13.92 ± 2.69		1.72 ± 0.19		7.53 ± 1.19

↵* P < 0.05.